Real-world data confirms the advantages of the FreeStyle Libre System

Pharmaceutical

Abbott’s FreeStyle Libre system is being used by over 1.5 million diabetics in 46 countries. Now researchers have evaluated records of 363 patients in Austria, France and Germany to determine the impact of using the FreeStyle Libre system on glycemic control for people living with type II diabetes on intensive insulin therapy. The results revealed that average HbA1c was 8.9% (73.3 mmol/mol) prior to FreeStyle Libre system use and 8.0% (63.6 mmol/mol) following use of the continuous glucose monitoring technology for at least three months, which is a significant reduction in glucose levels. This is the first time real-world data has been evaluated from type II diabetics who use the FreeStyle Libre system. There were no differences detected based on age group, gender, body mass index or duration of insulin use.

Abbott’s divisional vice president, global medical and scientific affairs, Diabetes Care, Mahmood Kazemi, said: "Doctors tell us that FreeStyle Libre is changing the course of care for people with diabetes, and the combination of these real-world data and clinical research is further proof that our technology delivers significant reductions in HbA1c in people with Type 2 diabetes. This adds to growing evidence from more than half a million users in real-world settings showing time after time, use of FreeStyle Libre is associated with improved glucose control and better health outcomes. With more than 425 million people living with diabetes around the world, there's an immense opportunity for Abbott's technology to change more lives and the future of those with diabetes."

“Real-world data confirms the advantages of the FreeStyle Libre System“

Helene Hanaire, University Hospital Center of Toulouse, and a lead author of the study, said: "These real-world findings highlight how Abbott's FreeStyle Libre system can fundamentally change how people manage their diabetes, especially for people living with Type 2 diabetes. By using the real-time results, trends and patterns from the technology right at their fingertips, people with diabetes are becoming more actively engaged in making better decisions to control their glucose levels and improve their own health."

See all the latest jobs in Pharmaceutical
Return to news